Vorsetuzumab mafodotin

Drug Profile

Vorsetuzumab mafodotin

Alternative Names: SGN-75

Latest Information Update: 17 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 31 Dec 2013 Seattle Genetics terminates phase I trial in Renal cancer (combination therapy) in USA (NCT01677390)
  • 06 Nov 2013 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (IV)
  • 06 Nov 2013 Discontinued - Phase-I for Renal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top